Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2011 (2011), Article ID 174132, 4 pages
http://dx.doi.org/10.1155/2011/174132
Case Report

Dexmedetomidine Use in the Setting of Cocaine-Induced Hypertensive Emergency and Aortic Dissection: A Novel Indication

Division of Cardiology, St. Luke's Roosevelt Hospital Center, University Hospital for College of Physicians and Surgeons of Columbia University, 1090 Amsterdam Avenue, New York, NY 10025, USA

Received 1 September 2010; Revised 17 May 2011; Accepted 14 June 2011

Academic Editor: Jagdish Butany

Copyright © 2011 Fahad Javed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Y. Hsue, C. L. Salinas, A. F. Bolger, N. L. Benowitz, and D. D. Waters, “Acute aortic dissection related to crack cocaine,” Circulation, vol. 105, no. 13, pp. 1592–1595, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Erbel, F. Alfonso, C. Boileau et al., “Diagnosis and management of aortic dissection,” European Heart Journal, vol. 22, no. 18, pp. 1642–1681, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. T. T. Tsai, C. A. Nienaber, and K. A. Eagle, “Acute aortic syndromes,” Circulation, vol. 112, no. 24, pp. 3802–3813, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. L. K. Bickerstaff, P. C. Pairolero, and L. H. Hollier, “Thoracic aortic aneurysms: a population-based study,” Surgery, vol. 92, no. 6, pp. 1103–1108, 1982. View at Google Scholar · View at Scopus
  5. I. Meszaros, J. Morocz, J. Szlavi et al., “Epidemiology and clinicopathology of aortic dissection,” Chest, vol. 117, no. 5, pp. 1271–1278, 2000. View at Google Scholar
  6. W. D. Clouse, J. W. Hallett Jr., H. V. Schaff et al., “Acute aortic dissection: population-based incidence compared with degenerative aortic aneurysm rupture,” Mayo Clinic Proceedings, vol. 79, no. 2, pp. 176–180, 2004. View at Google Scholar · View at Scopus
  7. J. L. AU Januzzi, E. M. Isselbacher, R. Fattori et al., “Characterizing the young patient with aortic dissection: results from the international registry of aortic dissection (IRAD),” Journal of the American College of Cardiology, vol. 43, no. 4, pp. 665–669, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. C. Daniel, T. T. Huynh, W. Zhou et al., “Acute aortic dissection associated with use of cocaine,” Journal of Vascular Surgery, vol. 46, no. 3, pp. 427–433, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. K. A. Eagle, E. M. Isselbacher, and R. W. DeSanctis, “Cocaine-related aortic dissection in perspective,” Circulation, vol. 105, no. 13, pp. 1529–1530, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. J. Axelrod, L. G. Whitby, and G. Hertting, “Effect of cocaine on the disposition of noradrenaline labelled with tritium,” Nature, vol. 187, no. 4737, pp. 604–605, 1960. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Muscholl, “Effect of cocaine and related drugs on the uptake of noradrenaline by heart and spleen,” BritishJournal of Pharmacology and Chemotherapy, vol. 16, pp. 352–359, 1961. View at Google Scholar · View at Scopus
  12. R. F. Furchgott, S. M. Kirpeker, M. Rieker, and A. Schwab, “Action and interactions of norepinephrine, tyramine, and cocaine on aortic strips of rabbit and left atria guinea pig and cat,” Journal of Pharmacology, vol. 142, pp. 39–58, 1963. View at Google Scholar
  13. J. H. Jaffe, “Drug addiction and drug abuse,” in The Pharmacologic Basis of Therapeutics, A. G. Gilman, T. W. Rall, A. S. Nies, and P. Taylor, Eds., pp. 539–546, Pergamon Press, New York, NY, USA, 1990. View at Google Scholar
  14. R. A. Gillis, Y. M. Hernandez, H. K. Erzouki et al., “Sympathetic nervous system mediated cardiovascular effects of cocaine are primarily due to a peripheral site of action of the drug,” Drug and Alcohol Dependence, vol. 37, no. 3, pp. 217–230, 1995. View at Publisher · View at Google Scholar
  15. W. Vongpatanasin, Y. Mansour, B. Chavoshan, D. Arbique, and R. G. Victor, “Cocaine stimulates the human cardiovascular system via a central mechanism of action,” Circulation, vol. 100, no. 5, pp. 497–502, 1999. View at Google Scholar · View at Scopus
  16. P. Duke, “Dexmedetomidine: a general overview,” International Congress and Symposium Series: Redefining Sedation, no. 221, pp. 11–22, 1998. View at Google Scholar
  17. R. Aantaa, J. Kanto, M. Scheinin, A. Kallio, and H. Scheinin, “Dexmedetomidine, an α2-adrenoceptor agonist, reduces anesthetic requirements for patients undergoing minor gynecologic surgery,” Anesthesiology, vol. 73, no. 2, pp. 230–235, 1990. View at Google Scholar · View at Scopus
  18. R. Aantaa, “Assessment of the sedative effects of dexmedetomidine, an α2-adrenoceptor agonist, with analysis of saccadic eye movements,” Pharmacology and Toxicology, vol. 68, no. 5, pp. 394–398, 1991. View at Google Scholar · View at Scopus
  19. K. Baddigam, P. Russo, J. Russo, and J. D. Tobias, “Dexmedetomidine in the treatment of withdrawal syndromes in cardiothoracic surgery patients,” Journal of Intensive Care Medicine, vol. 20, no. 2, pp. 118–123, 2005. View at Publisher · View at Google Scholar · View at PubMed
  20. G. R. Baumgartner and R. C. Rowen, “Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomized, controlled clinical trial,” Southern Medical Journal, vol. 84, no. 3, pp. 312–321, 1991. View at Google Scholar
  21. I. Dobrydnjov, K. Axelsson, L. Berggren, J. Samarutel, and B. Holmstrom, “Intrathecal and oral clonidine as prophylaxis for postoperative alcohol withdrawal syndrome: a randomized double-blinded study,” Anesthesia and Analgesia, vol. 98, no. 3, pp. 738–744, 2004. View at Google Scholar
  22. A. H. Lichtman, J. Fisher, and B. R. Martin, “Precipitated cannabinoid withdrawal is reversed by △9-tetrahydrocannabinol or clonidine,” Pharmacology Biochemistry and Behavior, vol. 69, no. 1-2, pp. 181–188, 2001. View at Publisher · View at Google Scholar
  23. P. C. Yam, A. Forbes, and W. J. Kox, “Clonidine in the treatment of alcohol withdrawal in the intensive care unit,” British Journal of Anaesthesia, vol. 68, no. 1, pp. 106–108, 1992. View at Google Scholar
  24. E. L. Hoder, J. F. Leckman, R. Ehrenkranz et al., “Clonidine in neonatal narcotic-abstinence syndrome,” The New England Journal of Medicine, vol. 305, no. 21, p. 1284, 1981. View at Google Scholar
  25. H. Ashton, “Benzodiazepine withdrawal: outcome in 50 patients,” British Journal of Addiction, vol. 82, no. 6, pp. 665–671, 1987. View at Google Scholar
  26. American Academy of Pediatrics Committee on Drugs, “Neonatal drug withdrawal (RE9746),” Pediatrics, vol. 6, pp. 113–117, 1998. View at Google Scholar
  27. B. C. McClain, L. A. Probst, E. Pinter, and M. Hartmannsgruber, “Intravenous clonidine use in a neonate experiencing opioid-induced myoclonus,” Anesthesiology, vol. 95, no. 2, pp. 549–550, 2001. View at Google Scholar
  28. G. A. Maccioli, “Dexmedetomidine to facilitate drug withdrawal,” Anesthesiology, vol. 98, no. 2, pp. 575–577, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. A. S. Multz, “Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal,” Anesthesia and Analgesia, vol. 96, no. 4, pp. 1054–1055, 2003. View at Google Scholar · View at Scopus
  30. J. C. Finkel and A. Elrefai, “The use of dexmedetomidine to facilitate opioid and benzodiazepine detoxification in an infant,” Anesthesia and Analgesia, vol. 98, no. 6, pp. 1658–1659, 2004. View at Google Scholar · View at Scopus
  31. W. Mo, J. A. Arruda, G. Dunea, and A. K. Singh, “Cocaine-induced hypertension: role of the peripheral sympathetic system,” Pharmacological Research, vol. 40, no. 2, pp. 139–145, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. J. B. Dyck and S. L. Shafer, “Dexmedetomidine pharmacokinetics and pharmacodynamics,” Anaesth Pharm Review, vol. 1, pp. 238–245, 1993. View at Google Scholar
  33. D. Kurnik, M. Muszkat, G. G. Sofowora et al., “Ethnic and genetic determinants of cardiovascular response to the selective α2-adrenoceptor agonist dexmedetomidine,” Hypertension, vol. 51, no. 2, pp. 406–411, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. G. Erkonen, F. Lamb, and J. D. Tobias, “High-dose dexmedetomidine-induced hypertension in a child with traumatic brain injury,” Neurocritical Care, vol. 9, no. 3, pp. 366–369, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus